|Table of Contents|

The predictive value of inflammatory markers combined with circulating tumor cell count in the efficacy of neoadjuvant chemotherapy in breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 06
Page:
1002-1006
Research Field:
Publishing date:

Info

Title:
The predictive value of inflammatory markers combined with circulating tumor cell count in the efficacy of neoadjuvant chemotherapy in breast cancer
Author(s):
SUN Dan1; ZHU Zhengqiu2; XING Awen1
1.Xuzhou Medical University，Jiangsu Xuzhou 221000,China；2.Department of Medical Oncology,Affiliated Hospital of Xuzhou Medical University，Jiangsu Xuzhou 221000,China.
Keywords:
breast cancer; neoadjuvant chemotherapy; pathologic complete response rate; inflammatory markers; circulating tumor cells
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2025.06.017
Abstract:
Objective:To explore the predictive value of inflammatory markers combined with circulating tumor cells on the efficacy of neoadjuvant chemotherapy for breast cancer.Methods：The clinical data of 125 breast cancer patients who received neoadjuvant chemotherapy in the Department of Medical Oncology of our hospital from January 2020 to December 2022 were retrospectively analyzed,and the patients were divided into 39 cases in the pCR group and 86 cases in the non-pCR group according to the treatment effect.Logistic stepwise regression was used to analyze the independent influencing factors of NAC efficacy in breast cancer,and receiver operating characteristic curve (ROC) was used to analyze the predictive value of inflammatory markers combined with circulating tumor cells on the efficacy of neoadjuvant chemotherapy in breast cancer.Results：Univariate analysis showed that HR status,Her-2 status,CTC status,LMR,PLR,NLR,SII,and SIRI were correlated with pCR (P＜0.05).There were no significant differences in age,BMI,menopause,T stage,N stage,and Ki-67 between the two groups (P＞0.05).Multivariate analysis showed that Her-2 status,CTC status,LMR,NLR,PLR,and SII were independent correlated factors affecting the efficacy of neoadjuvant chemotherapy for breast cancer (P＜0.05).The AUCs of LMR,NLR,PLR,SII,Her-2，CTC and joint prediction model Pre were 0.665,0.643,0.648,0.718,0.610，0.669 and 0.823,respectively.Conclusion：Inflammatory indicators such as LMR,NLR,PLR,SII and CTC status have good predictive value for the efficacy of neoadjuvant chemotherapy for breast cancer.

References:

［1］ SIEGEL RL,MILLER KD,FUCHS HE,et al.Cancer statistics,2022［J］.CA:A Cancer Journal for Clinicians,2022,71(1):7-33.
[2] SHIEN T,IWATA H.Adjuvant and neoadjuvant therapy for breast cancer［J］.Japanese Journal of Clinical Oncology,2020,50(3):225-229.
[3] BARBOSA C ROCHA F,FALCONE AB,BUZAID AC,et al.Neoadjuvant therapy for breast cancer treatment:an expert panel recommendation from the Brazilian Society of Breast Surgeons 2018［J］.Breast Cancer Research and Treatment,2018,172:265-272.
[4] SINGH N,BABY D,RAJGURU JP,et al.Inflammation and cancer［J］.Annals of African Medicine,2019,18(3):121-126.
[5] GUO W,LU X,LIU Q,et al.Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients:An updated meta-analysis of 17079 individuals［J］.Cancer Medicine,2019,8(9):4135-4148.
[6] KACAN T,BABACAN NA,SEKER M,et al.Could the neutrophil to lymphocyte ratio be a poor prognostic factor for non small cell lung cancers［J］.Asian Pacific Journal of Cancer Prevention,2014,15(5):2089-2094.
[7] YANG J,MA J,CHENG S,et al.The combination of plasma fibrinogen concentration and neutrophil lymphocyte ratio (F-NLR) as a prognostic factor of epithelial ovarian cancer［J］.OncoTargets and Therapy,2020,13:7283-7293.
[8] ZHOU S,YUAN H,WANG J,et al.Prognostic value of systemic inflammatory marker in patients with head and neck squamous cell carcinoma undergoing surgical resection［J］.Future Oncology,2020,16(10):559-571.
[9] CASTELLO A,CARBONE FG,ROSSI S,et al.Circulating tumor cells and metabolic parameters in NSCLC patients treated with checkpoint inhibitors［J］.Cancers,2020,12(2):487-501.
[10] HINZ S,HENDRICKS A,WITTIG A,et al.Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients - a prospective study［J］.BMC Cancer,2017,17(1):1-11.
[11] ZHOU S,WANG L,ZHANG W,et al.Circulating tumor cells correlate with prognosis in head and neck squamous cell carcinoma［J］.Technology in Cancer Research & Treatment,2021,20:1-9.
[12] VON MINCKWITZ G,HUANG CS,MANO MS,et al.Trastuzumab emtansine for residual invasive HER2-positive breast cancer［J］.New England Journal of Medicine,2019,38(7):617-628.
[13] YIP CH,RHODES A.Estrogen and progesterone receptors in breast cancer［J］.Future Oncology,2014,10(14):2293-2301.
[14] KRISHNAMURTI U,SILVERMAN JF.HER2 in breast cancer:a review and update［J］.Advances in Anatomic Pathology,2014,21(2):100-107.
[15] HAN X,LI H,DONG SS,et al.Application of triple evaluation method in predicting the efficacy of neoadjuvant therapy for breast cancer［J］.World Journal of Surgical Oncology,2023,21(1):116-124.
[16] ANDERSON NM,SIMON MC.The tumor microenvironment［J］.Current Biology,2020,30(16):R921-R925.
[17] 彭译漫,罗香梦,陈婧瑶.肿瘤微环境代谢的研究进展及免疫治疗新策略［J］.四川大学学报（医学版）,2023,54(3):505-509. PENG Yiman,LUO Xiangmeng,CHEN Jingyao.Research progress and new immunotherapy strategies of tumor microenvironment metabolism［J］.Journal of Sichuan University (Medical Sciences),2023,54(3):505-509.
[18] ZHAO H,WU L,YAN G,et al.Inflammation and tumor progression:signaling pathways and targeted intervention［J］.Signal Transduction and Targeted Therapy,2021,6(1):263-308.
[19] 李旭,郝宇,吴雪瑶,等.肥胖相关蛋白在女性乳腺癌发病中的交互作用初探［J］.四川大学学报（医学版）,2023,54(3):579-584. LI Xu,HAO Yu,WU Xueyao,et al.Effect of interactions among obesity-related proteins on breast cancer risk:A preliminary study［J］.Journal of Sichuan University (Medical Sciences),2023,54(3):579-584.
[20] KIM HY,KIM TH,YOON HK,et al.The role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in predicting neoadjuvant chemotherapy response in breast cancer［J］.Journal of Breast Cancer,2019,22(3):425-438.
[21] DONG J,SUN Q,PAN Y,et al.Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy［J］.BMC Cancer,2021,21(1):700-707.
[22] WANG L,ZHOU S,ZHANG W,et al.Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer:a retrospective study in 121 patients［J］.International Journal of Colorectal Disease,2019,34:589-597.
[23] HU B,YANG XR,XU Y,et al.Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma［J］.Clinical Cancer Research,2014,20(23):6212-6222.
[24] BIDARD FC,KIAVUE N,JACOT W,et al.Overall survival with circulating tumor cell count-driven choice of therapy in advanced breast cancer:A randomized trial［J］. Journal of Clinical Oncology,2024,42(4):383-389.
[25] WEI HW,QIN SL,XU JX,et al.Nomograms for postsurgical extrahepatic recurrence prediction of hepatocellular carcinoma based on presurgical circulating tumor cell status and clinicopathological factors［J］.Cancer Med,2023,12(14):15065-15078.

Memo

Memo:
-
Last Update: 1900-01-01